Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EX10
|
| gptkbp:brand |
gptkb:Vitrakvi
|
| gptkbp:CASNumber |
1223403-58-4
|
| gptkbp:chemicalClass |
small molecule
|
| gptkbp:developer |
gptkb:Bayer
gptkb:Loxo_Oncology |
| gptkbp:hasMolecularFormula |
C21H22F2N6O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
larotrectinib
|
| gptkbp:indication |
tumors with NTRK gene fusion regardless of tissue origin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
TRK inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea vomiting dizziness fatigue increased liver enzymes |
| gptkbp:target |
gptkb:NTRK1
gptkb:NTRK2 gptkb:NTRK3 |
| gptkbp:usedFor |
gptkb:cancer
solid tumors with NTRK gene fusion |
| gptkbp:bfsParent |
gptkb:TrkA
gptkb:Loxo_Oncology |
| gptkbp:bfsLayer |
6
|